preclinical studies – Page 3 – Communicable Diseases Research

Biomaterials and Oxygen Join Forces to Shape the Immune Response and Boost COVID‐19 Vaccines

생체 재료 및 산소 결합 힘을 결합하여 면역 반응을 형성하고 Covid -19 백신을 향상시킵니다.

Research Article

Published on 2021-07-202022-08-31
Journal: Advanced Science [Category] SARS, 치료제,

Women and babies are dying from inertia: a collaborative framework for obstetrical drug development is urgently needed

Research article

Published on 2021-07-012022-10-05
Journal: American journal of obstetrics and gynecology [Category] 비임상,

[키워드] absence addition Adverse reactions approval cause clinical development clinical trials with pregnant women clinician Complication complications develop drug drug candidate Drug development drug therapy effective facilitate fetal fetal growth restriction Guidance Health Inclusion Infants legislative framework limit morbidity Mortality obstetrical syndromes obstetrics pathophysiology patients pharmaceutical treatment placental transfer preclinical studies preeclampsia pregnancies Pregnancy pregnancy complications pregnant women prenatal preterm delivery preterm labor preterm premature rupture of membranes reduced Regulatory Research research and development Safe small for gestational age solution subject syndrome Therapies therapy translational Treatment treatment during pregnancy trials unmet need women
[DOI] 10.1016/j.ajog.2021.03.024 [Article Type] Research article

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody

초기 회복기 COVID-19 환자로부터 분리 된 강력한 SARS-COV-2 중화 항체, SC31의 FC- 매개 이펙터 기능은 항체의 최적의 치료 효능에 필수적이다.

Research Article

Published on 2021-06-232022-08-13
Journal: PLoS ONE [Category] Biochemistry, MERS, SARS, 변종, 유전자 메커니즘, 진단,

[키워드] ACE2 addition Administered animal models Anti-SARS-CoV-2 Activity anti-viral immune responses antibody Antibody-dependent enhancement Antibody-mediated neutralization convalescent convalescent patient COVID-19 COVID-19 patient demonstrated dose-dependent efficacy effective Efficacy epitope evidenced exhibited Fc-mediated effector function Fc-mediated effector functions Fc-null LALA variant Histopathology IFNγ immune responses Inflammatory responses K18-human ACE2 transgenic mice LALA variant Lower respiratory tract lung Lungs mice neutralization ability Neutralizing antibodies neutralizing antibody occur preclinical studies preclinical study prevented pro-inflammatory response pro-inflammatory responses promote Protein Receptor-binding domain reduced viral load reduced viral loads reduction respiratory rhesus macaques SARS-CoV-2 SARS-CoV-2 neutralizing antibody SARS-CoV-2 spike protein SARS-CoV-2-infected hamsters SARS-CoV-2-neutralizing antibodies SARS-CoV-2-neutralizing antibody SC31 SC31 treatment severity of COVID-19 significantly spike Spike protein sub-therapeutic doses the receptor-binding domain the SARS-CoV-2 therapeutic therapeutic efficacy therapeutic potential Therapeutics transgenic mice treated treatment with SC31 undetectable Viral Viral load viral loads viral-induced viral-induced lung inflammatory responses weight loss
[DOI] 10.1371/journal.pone.0253487 PMC 바로가기 [Article Type] Research Article

Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization

Tozinameran (BNT162B2) 백신 : 전임상 연구에서 임상 시험 및 승인으로의 여정

Review

Published on 2021-06-072022-08-31
Journal: AAPS PharmSciTech [Category] MERS, SARS, 신약개발, 임상, 진단,

[키워드] Administered administration adolescents adverse effects age antibody Antibody Response authorization bind BioNTech BNT162b1 BNT162b2 BNT162b2 vaccine BNT162b2 vaccines children clinical clinical trial clinical trials COVID-19 dosages Efficacy ENCODE EUA exhibited expected expression first dose host cells immune response Immunity individual Lipid nanoparticle Lipid nanoparticles mRNA Neutralizing antibodies of BNT162b2 Older operation participant Pfizer Pfizer-BioNTech Phase 1 phase 1 trials phase 1/2 trials Phase 2 phase 2 trials phase 2/ 3 trials phase 2/3 Phase 3 Phase 3 trials Preclinical preclinical studies preclinical trials pregnant pregnant women question real-world outcomes receive reported RNA robust S antigen Safety SARS-CoV-2 SARS-CoV-2 spike protein speed Spike protein Support the SARS-CoV-2 Tozinameran transfer Trial Vaccine
[DOI] 10.1208/s12249-021-02058-y PMC 바로가기 [Article Type] Review

Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

Article

Published on 2021-04-092022-10-04
Journal: NPJ Vaccines [Category] 비임상,

Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial

COVID-19에 대한 이트라코나졸: 전임상 연구 및 개념 증명 무작위 임상 시험

Randomized Controlled Trial

Published on 2021-03-192022-08-13
Journal: EBioMedicine [Category] MERS, SARS, 비임상, 신약개발, 임상, 진단, 치료제,

[키워드] 7-point ordinal scale 95% CI absence acute infection acute SARS-CoV-2 infection adequate plasma antifungal drug itraconazole antivirals assigned breath Caco-2 clinical status Clinical studies clinical study clinical trial COVID-19 cumulative score did not reduce drug concentrations Drug repurposing effective evaluated finding foundation funding geometric Geometric means Health Organization Horizon hospitalized COVID-19 patient hospitalized COVID-19 patients human Caco-2 cells ileum in vitro activity initial interim analysis itraconazole Leuven lung Lungs Melinda Gate Melinda Gates not effective Open-label Ordinal Scale outcome Preclinical preclinical studies preclinical study premature termination Prevent prevention of COVID-19 Primary outcome proof-of-concept clinical study randomized clinical trial Randomly required SARS-CoV-2 SARS-COV-2 infection showed no signal single-center study Standard of care Stool stools Transmission Transmission model Treatment Vero Viral Viral load viral load in lungs Viral transmission World Health Organization
[DOI] 10.1016/j.ebiom.2021.103288 PMC 바로가기 [Article Type] Randomized Controlled Trial

Mechanisms Modified by (−)-Epicatechin and Taxifolin Relevant for the Treatment of Hypertension and Viral Infection: Knowledge from Preclinical Studies

Review

Published on 2021-03-162022-10-28
Journal: The Cochrane database of systematic reviews [Category] COVID-19,

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies

비활성화된 SARS-CoV-2 백신의 면역원성과 안전성: 전임상 연구

Article

Published on 2021-03-032022-09-10
Journal: Vaccines [Category] 비임상,

[키워드] Antibody titers approved AstraZeneca booster booster dose breath candidate vaccine challenge clinical development clinical trial control group country effective Efficacy Emergency use experimental models guinea pigs hamster hamsters immunogenicity immunological profile inactivated increase in Infection Laboratory mice Moderna morbidity mRNA Neutralizing antibody titer neutralizing antibody titers pandemic performed Phase I PIGS post vaccination pre-clinical study Preclinical preclinical studies RATs Safety safety evaluation SARS-CoV-2 SARS-CoV-2 vaccine shedding Sinopharm subjects tested the vaccine tolerable Vaccine vaccine safety virus
[DOI] 10.3390/vaccines9030214 PMC 바로가기 [Article Type] Article

Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?

줄기 세포와 COVID-19: 인간 양막 세포는 SARS-CoV-2 바이러스에 대한 치료법에 대한 새로운 희망입니까?

Review

Published on 2021-03-012022-09-10
Journal: Stem Cell Research & Therapy [Category] 임상,

[키워드] Amnion amniotic anti-inflammatory properties applied caused Cell Cell therapy clinical trial clinical trials coronavirus COVID-19 COVID-19 treatment cytokine Diseases effective epithelial cell epithelial cells hAEC Health Human amniotic epithelial cells Human amniotic mesenchymal stromal cells in some in vivo models Inflammatory response Lung disease Lung diseases Lung infection Lung injury membrane Mesenchymal stem cells MSC MSCs New coronavirus pandemic Patient patients with COVID-19 Placenta positioned preclinical studies preclinical study problems producing Proinflammatory cytokine reduced regenerative respiratory Respiratory disease respiratory diseases restored Safe SARS-CoV-2 SARS-CoV-2 virus severe patients stem cell Stem cell therapy stem cells stromal cell stromal cells suggested term tested the SARS-CoV-2 the SARS-CoV-2 virus therapy therapy for COVID-19 tissue Treatment Trigger triggers
[DOI] 10.1186/s13287-021-02216-w PMC 바로가기 [Article Type] Review

Antiviral Activity of Vacuolar ATPase Blocker Diphyllin against SARS-CoV-2

Article

Published on 2021-02-252022-10-29
Journal: Microorganisms [Category] COVID-19,

[키워드] 50% effective concentration activity added analogue anti-SARS-CoV-2 antiviral activity approach ATPase blocker cells cellular cleistanthin B compounds Concentration coronavirus 2 COVID-19 Critical cytotoxicity death diphyllin disease Effect evaluated exhibit functional helioxanthin host cell in viral in vitro infected cells Infection inhibitor membranes pandemic coronavirus post infection preclinical studies profile Replication respiratory SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significant decrease the SARS-CoV-2 vacuolar vacuolar ATPase blocker Vero Cell Vero cells Vero E6 viral envelope virus
[DOI] 10.3390/microorganisms9030471 PMC 바로가기 [Article Type] Article